Log in to your Inderes Free account to see all free content on this page.
Diamyd Medical
13.18 SEK
+1.70 %
Less than 1K followers
DMYD B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+1.70 %
+17.05 %
+34.08 %
+19.82 %
+36.44 %
-28.50 %
-14.97 %
-55.90 %
+338.94 %
Diamyd Medical is active in diabetes research. The company has developed a vaccine that contains the active ingredient and molecule GAD, a substance that has the potential to be an important part of the prevention of diabetes treatments in the future. The company has operations on a global level with the largest presence in the Nordic region. The headquarters are located in Stockholm.
Read moreMarket cap
1.81B SEK
Turnover
5.82M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
28.1.
2026
Interim report Q1'26
25.3.
2026
Interim report Q2'26
24.6.
2026
Interim report Q3'26
All
Press releases
ShowingAll content types
Diamyd Medical AB: Diamyd Medical announces completion of screening in pivotal Phase 3 DIAGNODE-3 trial
Diamyd Medical AB: Diamyd Medical's lead immunotherapy for type 1 diabetes receives global non-proprietary name retogatein
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio